Evotec AG receives Investment Bank Analyst Rating Update
Evotec AG O.N. (DE:EVTG) ended 2016 with the landmark deal with Celgene (NASDAQ:CELG) for Evotec’s induced pluripotent stem cell (iPSC) platform, bringing in a $45m upfront...
C4X Discovery Holdings PLC (LON:C4XD) has announced a new strategic collaboration with Evotec AG O.N. (DE:EVTG), which builds on a previous agreement (January 2015) to develop new...
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
|Average||27.100 (+44.072% Upside)|
|No. of Analysts||13|